Clinical trialPhase 1Completed
ORB-011 In Patients With Advanced Solid Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 21 August 2023
- Ended
- 29 May 2026
- Enrollment
- 55 participants
- Sites
- 2
- Primary outcomes
- Number of Adverse Events (AE) in patients dosed with ORB-011; Determine Recommended Phase 2 Dose (RP2D)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 12 June 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The goal of this clinical research study is to determine if an investigational new drug, named ORB-011, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.
Detailed description public domain (ClinicalTrials.gov)
ORB-011 is a complex engineered biologic molecule that targets interferon alpha 2b activation specifically to type 1 conventional dendritic cells (cDC1). The interferon alpha 2b in ORB-011 is inactive to all other cell types but confers full activation in cis when bound to cDC1 cells which exclusively express CLEC9a, thereby eliminating the potential systemic toxicities caused by alpha interferon when binding to interferon receptors on other cells. ORB-1 is administered by intravenous (IV) infusion. In cancer patients, treatment may be repeated every 3 weeks.